Status:
UNKNOWN
New Biomarkers in the Prediction of Chemotherapy-induced Cardiotoxicity.
Lead Sponsor:
Cardiology Prague
Collaborating Sponsors:
BioVendor LM
Oncology Center Medicon
Conditions:
Cardiotoxicity
Chemotherapy Effect
Eligibility:
FEMALE
18+ years
Brief Summary
Early detection and thus rapid therapy of cardiotoxicity related to chemotherapy are essential for restoring cardiovascular function. The complete recovery of the cardiovascular system decreases with ...
Detailed Description
The most effective approach to minimizing the consequences of cardiotoxicity of oncological treatment is its early identification, adjustment of oncological treatment (change of procedure, dose, drugs...
Eligibility Criteria
Inclusion
- Breast cancer
- Chemotherapy with a known cardiotoxic side effect
Exclusion
- Known cardiovascular disease
Key Trial Info
Start Date :
September 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2025
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT05992337
Start Date
September 1 2021
End Date
January 1 2025
Last Update
August 16 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Cardiology Prague Ltd
Prague, Czechia, 10100
2
Oncology Center Medicon
Prague, Czechia